Patent · US Active

Oncolytic virus vector and application thereof

US11987802B2 · kind B2 · utility

0Cited by

0References

9Claims

0Family size

Assignee

SHANGHAI YUNYING BIOPHARMACEUTICAL TECHNOLOGY CO., LTD. · CN

Inventors

Ziying Gong · Shanghai, CN
Daoyun Zhang · Shanghai, CN
Yonghua Sun · Shanghai, CN
Yi Wang · Lanzhou, CN
Nan Shi · Newark, US
Jun Zhu · Chongqing, CN
Miao Ding · Shanghai, CN

Key dates

Filing date	Jul 11, 2023
Grant date	May 21, 2024
Priority date	—
Expiry date	Jul 11, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2710/16643
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The embodiments of the present disclosure may provide an oncolytic virus vector and an application thereof. The oncolytic virus vector may comprise a recombinant nucleic acid. The recombinant nucleic acid may include: (i) a first nucleic acid fragment encoding a soluble PD-1 molecule; (ii) a second nucleic acid fragment encoding a CD86 molecule; and (iii) a third nucleic acid fragment encoding an antibody to a CD3 molecule.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.